Bimeda Ireland is pleased to announce that Endofluke 100mg Oral Suspension (VPA No. 10960/046/001) has now been approved for use in dairy cows by the Irish Medicines Board (IMB), with a milk withdrawal period of 45 days + 48 hours. The IMB issued the approval on 21st November 2013. The updated SPC will be made available on the IMB’s website, within 14 days. However, in the meantime, a copy of the approved updated SPC is included with this announcement. Further information relating to this approval can be found on the following section of the IMB website.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole, is the only active ingredient licensed in Ireland that is proven to kill all three stages of liver fluke.
Bimeda Ireland Sales Manager Andrew Glynn, commented, ‘This is great news for Ireland’s dairy farmers. Endofluke has long been favoured by Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It has proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows is fantastic news for Ireland’s dairy farmers.’
Bimeda’s Commerical Vet, Padraig Hyland, added, ‘We are extremely happy to be able to now provide this tried and trusted fluke treatment to Ireland’s dairy farmers. As we are now at the start of the drying off and housing season, this announcement comes at an ideal time for farmers.’